Safety Analysis of Brentuximab Vedotin from the Phase III AETHERA Trial in Hodgkin Lymphoma in the Post-Transplant Consolidation Setting-Reference-Cited by-同舟云学术

Safety Analysis of Brentuximab Vedotin from the Phase III AETHERA Trial in Hodgkin Lymphoma in the Post-Transplant Consolidation Setting

Published:2018-11 Issue:11 Volume:24 Page:2354-2359
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Nademanee Auayporn,Sureda Anna,Stiff Patrick^ORCID,Holowiecki Jerzy,Abidi Muneer,Hunder Naomi,Pecsok Michael,Uttarwar Mayur,Purevjal Indra,Sweetenham John

Funder

Seattle Genetics, Inc.

Millennium Pharmaceuticals, Inc.

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference19 articles.

1. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial;Linch;Lancet,1993

2. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial;Schmitz;Lancet,2002

3. Does the addition of involved field radiotherapy to high-dose chemotherapy and stem cell transplantation improve outcomes for patients with relapsed/refractory Hodgkin lymphoma?;Kahn;Int J Radiat Oncol Biol Phys,2011

4. Hodgkin lymphoma: diagnosis and treatment;Ansell;Mayo Clin Proc,2015

5. American Society for Blood and Marrow Transplantation. Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation;Perales;Biol Blood Marrow Transplant,2015

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies;MedComm;2024-07-28

2. Cardiovascular Toxicity of Antineoplastic Treatments in Hematological Diseases: Focus on Molecular Mechanisms to Improve Therapeutic Management;Journal of Clinical Medicine;2024-03-09

3. Cardiac toxicity of brentuximab vedotin: a real-word disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-01-25

4. Risk of Severe Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies;Cureus;2024-01-10

5. A pharmacovigilance study on drug-induced liver injury associated with antibody-drug conjugates (ADCs) based on the food and drug administration adverse event reporting system;Expert Opinion on Drug Safety;2023-10-29